Biotech Startups

Grey Matter Neurosciences develops transcranial focused ultrasound systems combined with drug therapies to treat mood and cognitive disorders in older adults, with an initial focus on non-invasive neuromodulation outside hospital settings.

1 investor

Grown Alchemist develops high-performance skincare products that combine botanically-sourced ingredients with biotechnology, designed for consumers focused on skin health and wellness. The company operates flagship stores in Melbourne, London, and Hong Kong, and distributes through premium retailers globally.

1 investor

2NA FISH develops a spatial RNA detection platform using nanostructure-enhanced probes for oncology research and pathology workflows. The platform combines brightfield RNA biomarker analysis on standard fluorescence microscopes with AI-powered software for quantification and cell-level readouts.

1 investor

Grybas develops ecological materials grown from mushroom mycelium and agricultural residues as compostable alternatives to plastic foam for packaging, interiors, and everyday objects. It works with companies seeking to replace plastic foam and with designers, combining biotechnology and ecological design, and is based in Costa Rica.

1 investor

GT Bio develops an in vivo drug delivery atlas that combines drug delivery, targeted conjugates, spatial biology, and machine learning to enable cell type-specific delivery for precision medicine. The company generates in vivo delivery data intended to support the development of next-generation drug delivery systems for patients.

1 investor

Disruptive Pharma AB (formerly Guard Therapeutics International AB) is a pharmaceutical company listed on Nasdaq First North Growth Market under the ticker DPHA. The page contains shareholder and stock information but does not describe the company's products, therapeutic focus, or target markets.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor

A biotech company developing Microbiota Transplant Therapy (MTT), a patented treatment that restructures the gut microbiome to improve symptoms of Autism Spectrum Disorder and Pitt-Hopkins Syndrome. Its therapies are in Phase 2b clinical trials, with FDA submissions and Phase 3 planned for 2026.

1 investor

Gutcrine is a Danish biotech developing pharmabiotics derived from gut microbiome hormone synthesis, aimed at the prevention and treatment of cardio-metabolic disorders.

1 investor

GXP-Storage provides GxP-compliant regulated materials storage and lifecycle management for life sciences organizations across pre-clinical research, clinical trials, commercial manufacturing, and healthcare delivery. Its GXP-Guardian platform combines physical material records and secure e-archives into a single inspection-ready archive, serving life sciences sectors in the US and UK.

1 investor

Gyala Therapeutics develops autologous immunotherapy based on CAR-T technology targeting CD84 for cancer treatment. The company is a technology-based enterprise supported by Spanish government research and innovation programs.

1 investor

Gylden Pharma develops proprietary dermal delivery platforms for therapeutic medicines, using titanium microneedles and programmable gold nanoparticles to enable rapid, precise drug delivery through the skin. The company focuses on oncology and infectious disease applications including tumor immunotherapy and vaccine development.

1 investor

Gyre Therapeutics is a biopharmaceutical company developing small-molecule therapeutics for organ fibrosis and inflammatory diseases, with its lead program F351 in clinical evaluation for liver fibrosis in the US and China. The company also operates Cullgen Inc., a subsidiary focused on targeted protein degrader therapies for cancer and inflammatory conditions.

1 investor

Gyros Protein Technologies develops the Gyrolab platform, an immunoassay solution for bioprocess applications in the biotechnology industry. The platform enables automated protein analysis and characterization for biopharmaceutical development and manufacturing.

1 investor

H2OM develops an at-home saliva-based hormone sensing system that uses a countertop reader and clickable cartridges to measure five hormones (testosterone, cortisol, melatonin, DHEA and estradiol) and report levels via a phone app within a minute. Marketed as a consumer wellness product for tracking energy, stress, recovery and sleep, its technology is built in Canada and published in npj Biosensing.

1 investor

Haelixa is a deep tech company, spun off from ETH Zürich, that uses DNA-based markers to verify the origin and authenticity of physical products. Its technology serves textile traceability and luxury product anti-counterfeiting needs.

1 investor

Haemanthus is developing molecular-level diagnostic technology aimed at reading comprehensive molecular health data to detect disease earlier.

1 investor

Hale Animal Health develops novel veterinary pharmaceuticals for companion animals, focused on treatments intended to be effective and safe with fewer side effects. The company targets the pet health market.

1 investor

Halex Istar develops, manufactures, and sells ready-to-use injectable medications and large- and small-volume parenteral solutions for the hospital segment. Founded in 1959, the Brazilian pharmaceutical company serves clients nationwide and invests in R&D for incremental innovation in hospital care.

1 investor

Halo Pharma is a contract development and manufacturing organization (CDMO) that develops, scales, and manufactures small molecule drug products across dosage forms such as solids, liquids, semi-solids, and suppositories. It serves pharmaceutical innovators, generics, and OTC owners from two North American facilities in Whippany, NJ and Mirabel, QC, with regulatory approvals spanning FDA, Health Canada, EMA, and other agencies.

1 investor

AvantGuard develops Avantamine, an antimicrobial molecule that eliminates bacteria, viruses, and fungi on surfaces and skin without generating resistance, with an initial focus on topical treatment of the drug-resistant fungal pathogen Candida auris. The technology can be formulated as an antiseptic, disinfectant, surface coating, or plastics additive for use in healthcare settings.

1 investor

Gansu Haotian Pharma Tech, a subsidiary of Gansu Haotian Technology, develops, manufactures, and sells specialty active pharmaceutical ingredients (APIs) and intermediates and offers contract development and manufacturing services (CDMO/CMO) for new drugs. It operates production lines including high-potency API (OEB-4), photochemistry, enzymatic fermentation and catalysis, distillation, catalytic hydrogenation, and ultra-low temperature, based in Baiyin, Gansu, China.

1 investor

HaploX (海普洛斯) develops gene sequencing, liquid biopsy, and genomic big-data technologies for cancer detection and genetic screening. It runs a clinical laboratory providing genetic testing services and solutions to hospitals, research institutions, health-screening centers, insurers, and government bodies in China.

1 investor

HappiLabs offers a Virtual Lab Manager service, pairing PhD-level former scientists with software tools to handle lab purchasing, negotiating, inventory, bookkeeping, and safety/regulatory tasks. It serves principal investigators, startups, small biotechs, and larger pharma/biotech purchasing teams.

1 investor